Author:
Chalkia M. T.,Stefanoyiannis A. P.,Chatziioannou S. N.,Round W. H.,Efstathopoulos E. P.,Nikiforidis G. C.
Publisher
Springer Science and Business Media LLC
Subject
Radiology, Nuclear Medicine and imaging,Biomedical Engineering,Biophysics,General Physics and Astronomy
Reference84 articles.
1. Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares JE, Abdalla EK, Fleming JB, Vauthey JN, Rashid A et al (2008) One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 26:3063–3072. doi: 10.1200/JCO.2007.15.4377
2. Klimstra DS, Modlin IR, Coppola D, Lloyd RV, Suster S (2010) The pathologic classification of neuroendocrine tumors. A review of nomenclature, grading, and staging systems. Pancreas 39:707–712. doi: 10.1097/MPA.0b013e3181ec124e
3. Bodei L (2008) Peptide receptor radionuclide therapy with radiolabelled somatostatin analogues. Dissertation, University Medical Center Groningen
4. Novartis Oncology (2014) Multifaceted cancer that benefits from multidisciplinary care. http://www.neuroendocrinetumor.com/health-care-professional/managing-nets.jsp . Accessed on 29 March 2014
5. Zaknun JJ, Bodei L, Mueller-Brand J, Pavel ME, Baum RP, Hörsch D, O’Dorisio MS, O’Dorisiol TM, Howe JR, Cremonesi M et al (2013) The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours. Eur J Nucl Med Mol Imaging 40:800–816. doi: 10.1007/s00259-012-2330-6
Cited by
18 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献